Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01280149 · ClinicalTrials.gov registry record · Phase 1
Reduction of IgE Antibody in Human Allergic Subjects
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01280149 is a Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 40 participants.
The verdict
NCT01280149, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a neuropeptide, substance P, when injected along with an allergen, such as ragweed, can reduce allergic reactivity.
Interventions
- BIOLOGICAL substance P
- BIOLOGICAL substance P injections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-01 |
| Est. Completion | 2017-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01280149
The ClinicalTrials.gov registry entry for NCT01280149 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which substance P is the first listed.
NCT01280149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01280149 about?
NCT01280149 is a clinical study titled "Reduction of IgE Antibody in Human Allergic Subjects". The purpose of this study is to determine whether a neuropeptide, substance P, when injected along with an allergen, such as ragweed, can reduce allergic reactivity.
What is the current status of trial NCT01280149?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2011-01. Estimated completion is 2017-06-20.
What interventions are being tested in trial NCT01280149?
The interventions under investigation include: substance P (BIOLOGICAL), substance P injections (BIOLOGICAL).
Who is sponsoring clinical trial NCT01280149?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.